Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23


Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.

Abe F, Ueyama J, Kawasumi N, Nadai M, Hayashi T, Kato M, Ohnishi M, Saito H, Takeyama N, Hasegawa T.

Antimicrob Agents Chemother. 2008 Sep;52(9):3454-6. doi: 10.1128/AAC.00396-08. Epub 2008 Jun 30.


Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.

Lewis RE, Albert ND, Kontoyiannis DP.

J Antimicrob Chemother. 2008 May;61(5):1140-4. doi: 10.1093/jac/dkn069. Epub 2008 Feb 27.


Characterisation of the phagocytic uptake of Aspergillus fumigatus conidia by macrophages.

Luther K, Rohde M, Sturm K, Kotz A, Heesemann J, Ebel F.

Microbes Infect. 2008 Feb;10(2):175-84. doi: 10.1016/j.micinf.2007.11.001. Epub 2007 Nov 17.


Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258. No abstract available.


Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ.

Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. Epub 2007 Oct 15.


Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL.

Antimicrob Agents Chemother. 2008 Jan;52(1):92-7. Epub 2007 Oct 8.


Aspergillus fumigatus: principles of pathogenesis and host defense.

Hohl TM, Feldmesser M.

Eukaryot Cell. 2007 Nov;6(11):1953-63. Epub 2007 Sep 21. Review. No abstract available.


Effects of serum on in vitro susceptibility testing of echinocandins.

Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L.

Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6. Epub 2007 Sep 4.


Serum differentially alters the antifungal properties of echinocandin drugs.

Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS.

Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6. Epub 2007 Apr 9.


Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ.

J Infect Dis. 2007 Feb 1;195(3):455-66. Epub 2006 Dec 21.


Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.

Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A.

Antimicrob Agents Chemother. 2007 Feb;51(2):787-90. Epub 2006 Nov 20.


Micafungin: a new echinocandin.

Chandrasekar PH, Sobel JD.

Clin Infect Dis. 2006 Apr 15;42(8):1171-8. Epub 2006 Mar 14. Review.


Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.

Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S.

Transplantation. 2006 Feb 15;81(3):320-6.


Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Oct;45(10):1145-52.


Changing patterns and trends in systemic fungal infections.

Richardson MD.

J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i5-i11. Review.


Aspergillus infections in transplant recipients.

Singh N, Paterson DL.

Clin Microbiol Rev. 2005 Jan;18(1):44-69. Review.


Combination antifungal therapy for invasive aspergillosis.

Marr KA, Boeckh M, Carter RA, Kim HW, Corey L.

Clin Infect Dis. 2004 Sep 15;39(6):797-802. Epub 2004 Aug 27.


Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Conte JE Jr, Golden JA, Kipps J, McIver M, Zurlinden E.

Antimicrob Agents Chemother. 2004 Oct;48(10):3823-7.


Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE.

J Infect Dis. 2004 Oct 15;190(8):1464-71. Epub 2004 Sep 10.


Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP.

Chest. 2004 Mar;125(3):965-73.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk